Literature DB >> 12949941

Inhibition of prostate cancer cell growth by activated eosinophils.

Paulette Furbert-Harris1, Debra Parish-Gause, Ibrahim Laniyan, Keith A Hunter, Josephine Okomo-Awich, Theresa R Vaughn, Kesha C Forrest, Christina Howland, Abier Abdelnaby, Oladipo A Oredipe.   

Abstract

BACKGROUND: Host Immune response to prostate cancer primarily involves the CTL and NK effector cells. Recent immunotherapeutic strategies incorporating cytokine genes into the tumor cell and/or dendritic cells have had encouraging results. In this study, we describe the inhibitory activity of a third potential effector cell, the eosinophil, against DU 145 and PC-3 prostate tumor cells growth in vitro.
METHODS: Subconfluent monolayer cultures of DU 145 and PC-3 cells were incubated with peripheral blood eosinophils from allergic or asthmatic individuals and also with eosinophil cultured supernatants. Newly established eosinophil cell lines were also studied. After harvesting, the plates were washed and stained with Hematoxylin/eosin (H/E) then photographed. The combination of monolayer cell growth inhibition and colony formation inhibition assays were used to evaluate eosinophil inhibitory activity. In the colony formation inhibition assay one hundred cells per well in 6-well plates were incubated overnight, after which peripheral blood eosinophils, conditioned media and cytokines, IL-4 and TNF-alpha were added. The plates were harvested after 10 days incubation period. Colonies were stained and counted.
RESULTS: Hypo- and hyperdense peripheral blood eosinophils from allergic and asthmatic individuals as well as eosinophil cell lines established from these subpopulations inhibited both DU 145 and PC-3 cell growth at 58-78% and 10-38%, respectively. IL-5 up-regulated eosinophil cell line activity by 21-24%. The conditioned media which contained the released mediators of activated eosinophils were potent in their actions on both DU 145 and PC-3, inhibiting colony formation by as much as 90-100%.
CONCLUSION: These results clearly demonstrate the inhibitory potential of activated eosinophils and their released "soup" of mediators and therefore support the hypothesis that eosinophils may participate in host response to prostate cancer together with CTLs and NK cells. Furthermore, this study offers insights into possible strategies for enhancing eosinophilic activity in prostate cancer. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12949941     DOI: 10.1002/pros.10286

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  5 in total

Review 1.  Eosinophils in innate immunity: an evolving story.

Authors:  Revital Shamri; Jason J Xenakis; Lisa A Spencer
Journal:  Cell Tissue Res       Date:  2010-11-03       Impact factor: 5.249

2.  Asthma and risk of lethal prostate cancer in the Health Professionals Follow-Up Study.

Authors:  Elizabeth A Platz; Charles G Drake; Kathryn M Wilson; Siobhan Sutcliffe; Stacey A Kenfield; Lorelei A Mucci; Meir J Stampfer; Walter C Willett; Carlos A Camargo; Edward Giovannucci
Journal:  Int J Cancer       Date:  2015-02-27       Impact factor: 7.396

Review 3.  Eosinophils: The unsung heroes in cancer?

Authors:  Gilda Varricchi; Maria Rosaria Galdiero; Stefania Loffredo; Valeria Lucarini; Giancarlo Marone; Fabrizio Mattei; Gianni Marone; Giovanna Schiavoni
Journal:  Oncoimmunology       Date:  2017-11-13       Impact factor: 8.110

4.  Chronic oral exposure to glycated whey proteins increases survival of aged male NOD mice with autoimmune prostatitis by regulating the gut microbiome and anti-inflammatory responses.

Authors:  Yingjia Chen; Kevin M Guo; Tamas Nagy; Tai L Guo
Journal:  Food Funct       Date:  2020-01-29       Impact factor: 5.396

5.  Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors.

Authors:  Sonja C S Simon; Xiaoying Hu; Jasper Panten; Mareike Grees; Simon Renders; Daniel Thomas; Rebekka Weber; Torsten J Schulze; Jochen Utikal; Viktor Umansky
Journal:  Oncoimmunology       Date:  2020-02-15       Impact factor: 8.110

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.